In the present study we used data from French-Canadian families included in the INHERIT program to evaluate the mutation risk prediction models BOADICEA and BRCAPRO [14,16] and to estimate the breast and ovarian cancer risks conferred by BRCA1 and BRCA2 mutations. This evidence concerns the gene BRCA2 and ovarian carcinoma.